Login / Signup

Comparative proteomics reveals a diagnostic signature for pulmonary head-and-neck cancer metastasis.

Hanibal BohnenbergerLars KaderaliPhilipp StröbelDiego YepesUwe PlessmannNeekesh V DhariaSha YaoCarina HeydtSabine Merkelbach-BruseAlexander EmmertJonatan HoffmannJulius BodemeyerKirsten Reuter-JessenAnna-Maria LoisLeif Hendrik DrögePhilipp BaumeisterChristoph WalzLorenz BiggemannRoland WalterBjörn HäuplFederico ComoglioKuan-Ting PanSebastian ScheichChristof LenzStefan KüfferFelix BremmerJulia KitzMaren SitteTim BeißbarthMarc HinterthanerMartin SebastianJoachim LotzHans-Ulrich SchildhausHendrik WolffBernhard C DannerChristian BrandtsReinhard BüttnerMartin CanisKimberly StegmaierHubert ServeHenning UrlaubThomas Oellerich
Published in: EMBO molecular medicine (2019)
Patients with head-and-neck cancer can develop both lung metastasis and primary lung cancer during the course of their disease. Despite the clinical importance of discrimination, reliable diagnostic biomarkers are still lacking. Here, we have characterised a cohort of squamous cell lung (SQCLC) and head-and-neck (HNSCC) carcinomas by quantitative proteomics. In a training cohort, we quantified 4,957 proteins in 44 SQCLC and 30 HNSCC tumours. A total of 518 proteins were found to be differentially expressed between SQCLC and HNSCC, and some of these were identified as genetic dependencies in either of the two tumour types. Using supervised machine learning, we inferred a proteomic signature for the classification of squamous cell carcinomas as either SQCLC or HNSCC, with diagnostic accuracies of 90.5% and 86.8% in cross- and independent validations, respectively. Furthermore, application of this signature to a cohort of pulmonary squamous cell carcinomas of unknown origin leads to a significant prognostic separation. This study not only provides a diagnostic proteomic signature for classification of secondary lung tumours in HNSCC patients, but also represents a proteomic resource for HNSCC and SQCLC.
Keyphrases